LGG Probiotic for Children: What the Research Shows About Safety, Diarrhea, and Daily Use

Parents looking at probiotics for their kids face a confusing market. Strain names get mixed up with marketing claims, doses range across two orders of magnitude, and most product labels treat children as scaled-down adults. The actual pediatric evidence is narrower than the shelf would suggest, and it is concentrated on a small number of strains. Lactobacillus rhamnosus GG, usually written LGG, is one of the most studied of those strains.

This article walks through what the research actually shows for LGG in children. It covers the conditions where the evidence is strongest, the conditions where it is weak or null, the safety record, and how to think about dosing. The aim is to give parents and clinicians a clear picture, not a sales pitch.

What LGG Is and Why Strain Specificity Matters

Lactobacillus rhamnosus GG was isolated by Sherwood Gorbach and Barry Goldin in 1983 (patent filed 1985), and the GG designation comes from their surname initials. It is a single, named strain with a specific genome and a specific behavioral profile in the gut. That distinction matters because probiotic effects do not generalize across species or even within a species. A study showing benefit from LGG does not automatically apply to a different strain of L. rhamnosus, much less to a different Lactobacillus species.

The clinical literature on LGG in children spans roughly four decades and covers thousands of participants across multiple countries. This is unusual in the probiotic space, where many products are sold on the strength of mechanism or category-level claims rather than strain-specific human data. When evaluating any probiotic product for a child, the first question is whether the studied effect is tied to the exact strain in the product. For LGG, the answer for several pediatric indications is yes.

Acute Infectious Diarrhea

Acute gastroenteritis is one of the most common reasons children see a doctor in early childhood. The condition is usually viral in origin, frequently rotavirus or norovirus, and the main clinical risk is dehydration. Oral rehydration is the cornerstone of treatment. Probiotics have been investigated as an adjunct to shorten duration and reduce stool output.

LGG is one of the two strains most commonly cited in pediatric gastroenteritis guidelines, alongside Saccharomyces boulardii. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Paediatric Infectious Diseases (ESPID) published a joint evidence-based guidelines update in 2014, led by Guarino and colleagues (PMID 24739189), that listed LGG among the strains with the strongest evidence for use in acute gastroenteritis in otherwise healthy children. Subsequent updates have moved the field toward more cautious language, reflecting heterogeneity in trial results across regions and populations.

Two large multicenter randomized controlled trials published in 2018 challenged the previously assumed magnitude of effect. Schnadower and colleagues, in the New England Journal of Medicine, found no significant difference in moderate-to-severe diarrhea outcomes when LGG was added to standard care in U.S. emergency department patients. Freedman and colleagues, also in NEJM and the same year, reported similar null findings with a different multi-strain probiotic in Canadian pediatric emergency settings. These results pushed the field toward acknowledging that earlier meta-analyses, which showed modest reductions in diarrhea duration on the order of 24 hours, may have been influenced by smaller, lower-quality trials and by population differences.

The honest summary is that LGG remains one of the better-studied options for pediatric acute gastroenteritis, and earlier evidence suggested a modest benefit, but two large rigorous trials in well-resourced emergency settings did not replicate that benefit. Parents and clinicians considering LGG in this context should expect, at most, a modest reduction in symptom duration, and should not view it as a substitute for oral rehydration.

Antibiotic-Associated Diarrhea

When children take broad-spectrum antibiotics, disruption of the gut microbiota can cause loose stools or diarrhea in roughly 10 to 20 percent of cases, depending on the antibiotic class and the age of the child. Antibiotic-associated diarrhea (AAD) in children is usually self-limiting but can be disruptive, painful, and occasionally severe.

The pediatric evidence here is more consistent than for acute gastroenteritis. Goldenberg and colleagues published a Cochrane systematic review in 2015 (PMID 26695080) that included 23 trials with 3,938 children and concluded that probiotics, particularly LGG and Saccharomyces boulardii at higher doses, reduced the incidence of AAD compared with placebo or no treatment. The number needed to treat to prevent one case of AAD was roughly 10, which is clinically meaningful when scaled across the population of children prescribed antibiotics.

Szajewska and Kolodziej published a focused systematic review of LGG specifically for AAD in children in 2015 (PMID 26365389). They identified five trials including over 400 children and found a statistically significant reduction in AAD incidence, with relative risk reductions in the range of 50 percent and a number needed to treat of approximately 8. The doses used in these trials were generally in the range of 1 to 10 billion CFU per day, given concurrently with antibiotics and continued for several days after the antibiotic course ended.

For parents whose child has just been prescribed an antibiotic, this is the indication where LGG has the cleanest pediatric evidence. The intervention is short, the side effect risk is low, and the magnitude of benefit is well-defined. Our deeper coverage of this topic is in our LGG for antibiotic-associated diarrhea article.

Respiratory and Common Cold Outcomes

A separate body of work has examined whether LGG affects the frequency or severity of common childhood respiratory infections, particularly in daycare settings. The hypothesis is that gut microbiota influence on immune function might extend to respiratory mucosal immunity.

Hatakka and colleagues published one of the earliest trials in this space in 2001 in BMJ, randomizing 571 Finnish daycare children to milk fortified with LGG or plain milk for seven months. They reported a modest reduction in respiratory infection days and antibiotic use, though absolute reductions were small. Hojsak and colleagues conducted two LGG trials in Croatian children in 2010, one in daycare settings published in Clinical Nutrition (PMID 19896252) reporting reduced upper respiratory infections and antibiotic use, and one in hospitalized children published in Pediatrics (PMID 20403940) reporting reduced nosocomial respiratory and gastrointestinal infections.

Subsequent systematic reviews have tempered enthusiasm. The evidence base for respiratory outcomes is smaller and less consistent than for diarrhea outcomes, and effect sizes are modest at best. Parents considering LGG primarily for cold prevention in daycare-age children should expect the evidence to be suggestive rather than definitive.

Atopic Conditions and Eczema

LGG has also been studied in the prevention and management of atopic dermatitis (eczema) in early childhood. Early trials by Kalliomaki and colleagues, beginning in The Lancet in 2001, reported reduced eczema incidence in high-risk infants whose mothers took LGG during late pregnancy and continued in the infant during the first six months of life. Follow-up trials produced mixed results, and a 2008 trial by Kopp and colleagues found no preventive effect in a similar high-risk population.

The current state of the eczema evidence is that LGG may offer modest benefit in some populations for prevention of atopic dermatitis when used perinatally, but the effect has not replicated cleanly across all trials. Treatment of established eczema with LGG has shown little benefit. This is a use case where parents should set expectations cautiously and discuss with a pediatric allergist or dermatologist rather than self-prescribe.

Functional Abdominal Pain and IBS in Children

Children with recurrent functional abdominal pain or pediatric irritable bowel syndrome represent another studied indication. Francavilla and colleagues conducted a randomized controlled trial in 2010 (PMID 21078735) in children with functional abdominal pain and pediatric IBS, finding that LGG at 3 billion CFU twice daily for eight weeks reduced the frequency and severity of pain compared with placebo, with the most consistent benefit in the IBS subgroup.

A subsequent meta-analysis by Horvath and colleagues in 2011 (PMID 21507030) pooled three trials of LGG in pediatric functional abdominal pain disorders and reported a moderate increase in treatment response (RR 1.31, NNT 7), with a larger effect in the IBS subgroup (RR 1.70, NNT 4). The evidence is limited but reasonably consistent for this indication, and LGG is one of the few probiotics with positive pediatric IBS data. Adult coverage of this topic is in our LGG for IBS article.

Safety in Children

The safety profile of LGG in healthy children is excellent. Decades of use in foods, infant formulas, and supplements have generated a large real-world safety database. Reported side effects in clinical trials are uncommon and typically mild, consisting of bloating or transient changes in stool consistency in the first few days of use.

The important safety caveat is that probiotics, including LGG, are not appropriate for severely immunocompromised children, children with central venous catheters, or children with serious underlying medical conditions without explicit clinical guidance. Rare cases of bacteremia attributed to LGG have been reported in such populations. For otherwise healthy children, the safety record is reassuring. Salminen and colleagues have published surveillance data tracking LGG safety over multiple decades in Finland, where it is widely consumed, with no signal of population-level harm.

Premature infants are a separate special population. Probiotic use in this group is an area of active research and clinical guideline development, and decisions in this setting belong to neonatologists, not to over-the-counter supplement choices.

How to Think About Dosing for Children

The dose range used in pediatric LGG trials spans roughly 1 to 10 billion CFU per day, with most trials clustering at 1 to 6 billion CFU per day. Higher doses have been studied in some AAD prevention contexts. There is no compelling evidence that pediatric doses above 10 billion CFU per day produce greater benefit than doses in the studied range.

This is a key consideration when selecting a product for a child. Our LGG supplement provides 30 billion CFU per capsule, which is an adult-oriented dose well above the pediatric trial range. Parents looking for a pediatric LGG product should consult their pediatrician about whether to use a lower-dose pediatric-specific format, whether to use a partial dose of an adult product, or whether a different product is more appropriate for their child's age and indication. We do not recommend giving a 30 billion CFU adult capsule to a young child without clinical guidance.

For older children and adolescents who can take adult-format supplements and who have a clear indication, 30 billion CFU is within the range of doses that have been used safely in adult and adolescent LGG trials. The decision to use any probiotic in a child should still flow through a conversation with a clinician.

Practical Takeaways

The cleanest pediatric indication for LGG is prevention of antibiotic-associated diarrhea, where the evidence is consistent, the intervention is short, and the magnitude of benefit is meaningful. Acute infectious diarrhea is a more contested indication, with earlier positive evidence and recent large null trials. Respiratory infections and eczema show modest, inconsistent benefit. Functional abdominal pain and pediatric IBS show promising but limited data.

Safety in healthy children is excellent, with the standard exclusions for severely immunocompromised populations. Dosing in pediatric trials is generally below 10 billion CFU per day, which is below our adult product dose and should inform product selection for younger children.

If you are reading this because your child has just been prescribed an antibiotic and you want to reduce the chance of diarrhea, LGG is one of the better-supported options in the literature. For ongoing daily use without a specific indication, the evidence is thinner. As with any pediatric supplement decision, the conversation with your pediatrician matters more than any single article.

For adult LGG use cases, see our LGG benefits and research overview. To explore the product itself, visit our LGG probiotic page.